AI-generated content for informational purposes only. Not financial advice. Always do your own research.

About

Becton Dickinson is a global medical technology company that manufactures syringes, needles, diagnostic instruments, medication management systems, and laboratory equipment used by healthcare institutions worldwide. The company is a Dividend Aristocrat with over 50 consecutive years of dividend increases, reflecting its durable competitive advantages and essential product portfolio. BDX attracts income-oriented investors who want reliable exposure to the healthcare sector.

Blue Chip Stocks

With over a century of operating history, a global distribution network reaching healthcare institutions in virtually every country, and consistent earnings growth, Becton Dickinson is a reliable blue chip in the medical technology space.

Dividend Stocks

Becton Dickinson is a Dividend Aristocrat with over 50 consecutive years of annual dividend increases, supported by the non-discretionary nature of its medical supply products that generate stable cash flows in any economic environment.

Healthcare Stocks

Becton Dickinson supplies the syringes, needles, IV catheters, diagnostic systems, and medication management platforms that hospitals and clinics around the world depend on daily, making it an indispensable healthcare stock.

Key Financials BDX

Price $175.89
Change (1D) -1.08%
Change (30D) +15.28%
Change (60D) +17.15%
Change (90D) +16.53%
Change (180D) +29.32%
Change (1Y) -0.94%
Change (5Y) -9.77%
P/E Ratio 12.65
EPS (TTM) $13.90
52-Week Range $127.59 โ€” $185.02
50-Day MA $159.08
Volume 3.17M

Data updated Feb 15 ยท Source: Twelve Data

4.1 2 reviews

AI Reviews

๐Ÿค–
3.7 /5

Becton Dickinson is a global medical technology leader specializing in medical devices, instrument systems, and reagents. The company holds dominant positions in syringes, needles, and diagnostic systems, providing a durable competitive moat. At a P/E of 12.65 with EPS of $13.90, BDX appears attractively valued relative to healthcare peers, though this may reflect market concerns about growth trajectory.

The bull case centers on BD's essential product portfolio, recurring revenue streams, and recent strong momentum " up 29% over six months with the stock trading well above its 50-day moving average. The planned separation of its Biosciences segment could unlock shareholder value.

However, the bear case is notable: the stock is down nearly 10% over five years, significantly underperforming the broader market. Integration challenges from the Alaris infusion pump recall and elevated debt from acquisitions remain headwinds. The dividend yield, while supported by a 50+ year growth streak, is modest. BD offers defensive healthcare exposure but has struggled to deliver meaningful capital appreciation, making it better suited for income-oriented, conservative portfolios.

Category Ratings

Blue Chip Stocks
3.8
Dividend Stocks
3.5
Healthcare Stocks
3.7
Feb 15, 2026
AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more
๐Ÿค–
4.5 /5
Becton Dickinson (BDX) remains a cornerstone of the medical technology sector, providing essential consumables and diagnostic systems that create a wide economic moat. Currently trading significantly below its 52-week high and well under its 50-day moving average, the stock presents a potential value opportunity for contrarian investors. With a P/E ratio of approximately 13, BDX is priced attractively compared to historical norms and broader healthcare indices, suggesting the market has priced in significant pessimism. While the company faces near-term headwinds regarding margins and operational execution, its status as a Dividend Aristocrat underscores its financial resilience and long-term commitment to shareholder returns. For investors seeking a defensive healthcare play with reliable cash flows and limited downside risk at this valuation, BDX offers a compelling entry point, though patience may be required for a technical trend reversal.

Category Ratings

Blue Chip Stocks
4.6
Dividend Stocks
4.7
Healthcare Stocks
4.3
Feb 12, 2026
AI-Generated Review Generated via Google API. This is an automated evaluation, not a consumer review. Learn more
Becton Dickinson Screenshot

Added: Feb 11, 2026

bd.com